Perceptions of Severe Asthma and Asthma–COPD Overlap Syndrome Among Specialists: A Questionnaire Survey

Sang-Heon Kim,1 Ji Yong Moon,1 Jae Hyun Lee,2 Ga-Young Ban,3 Sujeong Kim,4 Mi-Ae Kim,5 Joo-Hee Kim,6 Min-Hye Kim,7 Chan-Sun Park,8 So-Young Park,9 Hyouk-Soo Kwon,9 Jae-Woo Kwon,10 Jae-Woo Jung,11 Hye-Ryun Kang,12 Jong-Sook Park,13 Tae-Bum Kim,6 Heung-Woo Park,12 You Sook Cho,14 Kwang-Ha Yoo,14 Yeon-Mok Oh,15 Byung-Jae Lee,16 An-Soo Jang,13 Sang-Heon Cho,12 Hae-Sim Park,17 Choon-Sik Park,13 Ho Joo Yoon,* on behalf of the Severe Asthma Work Group, the Korean Academy of Asthma, Allergy and Clinical Immunology

1Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
2Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
3Department of Pulmonary, Allergy and Critical Care Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
4Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea
5Department of Internal Medicine, CHA University School of Medicine, Seongnam, Korea
6Department of Internal Medicine, Hallym University College of Medicine, Anyang, Korea
7Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea
8Department of Internal Medicine, Inje University College of Medicine, Busan, Korea
9Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
10Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea
11Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea
12Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
13Department of Internal Medicine, Soochunhyang University College of Medicine, Bucheon, Korea
14Department of Internal Medicine, Konkuk University, School of Medicine, Seoul, Korea
15Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
16Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea
17Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea

Purpose: Severe asthma and asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) are difficult to control and are often associated with poor clinical outcomes. However, much is not understood regarding the diagnosis and treatment of severe asthma and ACOS. To evaluate the current perceptions of severe asthma and COPD among asthma and COPD specialists, we designed an e-mail and internet-based questionnaire survey. Methods: Subjects were selected based on clinical specialty from among the members of the Korean Academy of Asthma, Allergy and Clinical Immunology and the Korean Academy of Tuberculosis and Respiratory Diseases. Of 432 subjects who received an e-mail invitation to the survey, 95 subjects, including 58 allergists and 37 pulmonologists, responded and submitted their answers online. Results: The specialists estimated that the percentage of severe cases among total asthma patients in their practice was 13.9% ± 11.0%. Asthma aggravation by stepping down treatment was the most common subtype, followed by frequent exacerbation, uncontrolled asthma despite higher treatment steps, and serious exacerbation. ACOS was estimated to account for 20.7% of asthma, 38.0% of severe asthma, and 30.1% of COPD cases. A history of smoking, persistently low forced expiratory volume in 1 second (FEV1), and low FEV1 variation were most frequently classified as the major criteria for the diagnosis of ACOS among asthma patients. Among COPD patients, the highly selected major criteria for ACOS were high FEV1 variation, positive bronchodilator response, a personal history of allergies and positive airway hyperresponsiveness. Allergists and pulmonologists showed different assessments and opinions on asthma phenotyping, percentage, and diagnostic criteria for ACOS. Conclusions: Specialists had diverse perceptions and clinical practices regarding severe asthma and ACOS patients. This heterogeneity must be considered in future studies and strategy development for severe asthma and ACOS.

Key Words: Severe asthma; asthma-chronic obstructive pulmonary disease overlap syndrome; perception
INTRODUCTION

Some patients with asthma fail to achieve acceptable control of their symptoms despite active treatment and modification of comorbidities. Severe asthma is often defined as asthma requiring a high level of treatment to prevent it from becoming or remaining uncontrolled.\(^1,2\) Poor control of severe asthma is associated with frequent exacerbation, high medical costs, and mortality.\(^3,4\) Even with vigorous research to understand severe asthma, neither an effective nor a comprehensive strategy has been determined to diagnose and treat severe asthma in clinical practice.

Some patients with asthma or chronic obstructive pulmonary disease (COPD) show features of both diseases, which are often determined to be asthma-COPD overlap syndrome (ACOS).\(^5\) Many patients with previously diagnosed asthma or COPD alone are now recognized to have ACOS, particularly elderly patients.\(^6\) Furthermore, ACOS has been found to have worse health outcomes than asthma or COPD alone in terms of comorbidities, exacerbation frequencies, lung function decline, medication costs, and mortality.\(^7,10\) Like severe asthma, ACOS is hard to manage due to the lack of sound evidence for proper management. To date, prospective randomized controlled trials have not determined uniform diagnostic criteria\(^11\) or an effective therapeutic strategy for ACOS.\(^12\)

Despite increased interest and research, there is a grey zone in clinical practices concerning severe asthma and ACOS that has not been well addressed in the guidelines of the Global Initiative for Asthma (GINA)\(^13\) or the Global Initiative for Chronic Obstructive Lung Disease (GOLD).\(^14\) While a majority of the patients with severe asthma or ACOS are frequently referred to specialists, even the specialists’ practices for those patients have not been standardized. The purpose of this study was to investigate the current perceptions and practices of severe asthma and ACOS among asthma and COPD specialists. Using a questionnaire, we asked specialists how they diagnose and treat patients with severe asthma or ACOS.
E-mail and online survey
We sent e-mails to 432 subjects containing an invitation to the online questionnaire. The subjects who agreed to participate accessed the questionnaire via the website link provided in the e-mail. The subjects were informed that their answers would be gathered anonymously. Usually, it took approximately 10 to 15 minutes to answer all of the questions. Invitation e-mails were sent up to three times. Of the 432 subjects who received the invitation e-mail, 95 (22.0%) submitted answers to the questionnaire.

Statistical analysis
We used SPSS Statistics for Windows (Version 21.0, IBM Corp., Armonk, NY, USA) for statistical analysis. For each multiple-choice question, the number and percentage of the respondents are shown as number (%). May of the questions with numerical answers asked for percentages of patients; those data are presented as the mean ± standard deviation. Comparisons between allergists and pulmonologists were performed using a χ² test (for nominal variables) or a Student’s t-test (for continuous variables). P values < 0.05 were considered significant.

RESULTS
Characteristics of the respondents
The demographics and patterns of the clinical practices of the subjects (n=95) are presented in Table 1. All specialists were Korean and were certified internists. By subspecialty, there were 58 allergists (61.1%) and 37 pulmonologists (38.9%). Most respondents worked in university hospitals (n=77, 81.1%); others were in general hospitals (n=9, 9.5%) or private clinics (n=9, 9.5%). Most specialists (n=85, 89.5%) accepted adult patients only; others (n=10, 10.5%) accepted both adults and children. There were significant differences in age, gender, and institution of employment between the allergists and pulmonologists.

Diagnosis of severe asthma
First, we attempted to assess the percentage of patients with severe asthma among all patients with asthma. To this purpose, we asked the specialists to provide the approximate percentage of severe asthma patients among total asthma patients in their clinical practice using an open-ended question. The mean percentage of severe asthma was 13.9%±11.0%, with a wide variance of estimation (range, 1%–70%; interquartile range [IQR], 5–20). There was no difference between allergist and pulmonologist responses (Fig. 1). As severe asthma is highly heterogeneous and includes different subtypes, we attempted to assess the variety of clinical features of severe asthma. We asked the subjects to estimate the percentage of patients with each subtype listed in the American Thoracic Society (ATS) guidelines among their patients with severe asthma. The most commonly reported subtype was aggravation of symptoms due to stepping down to GINA asthma management step 3 or lower (22.4%±20.9%), followed by frequent exacerbation (2 or more occasions of oral corticosteroid bursts per year; 20.9%±17.8%), uncontrolled asthma even at GINA step 4 or 5 (13.5%±12.6%), and serious exacerbation (one or more hospitalizations per year;...
12.8% ± 10.8%) (Fig. 2). There were no significant differences in the estimated percentages of each subtype of severe asthma between the allergists and pulmonologists.

Next, we attempted to assess how frequently different diagnostic tests were used to determine asthma phenotypes in clinical practice. The subjects were requested to select the tests that were usually performed at their practice to determine the phenotype of severe asthma. The most frequently used tests for asthma phenotyping were peripheral blood counts (93.7%), skin prick tests (SPTs), serum specific immunoglobulin E (sIgE) (93.7%), and the measurement of serum total IgE (93.7%) (Table 2). Other tests included chest computed tomography (CT) (65.3%), induced sputum analysis (45.3%), measurement of exhaled nitric oxide (26.3%), and the aspirin provocation test (16.8%). Allergists used induced sputum analysis, exhaled nitric oxide, and the aspirin provocation test more frequently than pulmonologists, while pulmonologists tended to use peripheral blood cell counts more frequently than allergists.

### Treatment of severe asthma

In the management of patients with severe asthma, poor response to medication is challenging. These patients fail to achieve or maintain asthma control even at a higher level of asthma management, including high dose inhaled corticosteroids (ICS) and long-acting beta-2 agonists (LABA). Thus, we attempted to assess what medications are used for pharmacologic treatment of severe asthma. The subjects were asked to estimate the percentage of patients using each medication added to high-dose ICS/LABA and leukotriene receptor antagonists. The most frequently used add-on medications were theophylline (46.0% ± 32.7%).

![Fig. 3. Estimated percentage of patients with severe asthma who were prescribed add-on asthma controllers.](https://doi.org/10.4168/aair.2018.10.3.225)

### Table 2. Diagnostic tests used to determine the phenotypes of severe asthma

| Test                          | Total (n=95) | Allergists (n=58) | Pulmonologists (n=37) | P value* |
|-------------------------------|-------------|-------------------|-----------------------|----------|
| Peripheral blood cell counts | 89 (93.7)   | 52 (89.7)         | 37 (100.0)            | 0.043    |
| SPT or serum specific IgE    | 89 (93.7)   | 55 (94.8)         | 34 (91.9)             | 0.566    |
| Serum total IgE              | 89 (93.7)   | 54 (93.1)         | 35 (94.6)             | 0.771    |
| Chest CT                     | 62 (65.3)   | 42 (72.4)         | 20 (54.1)             | 0.067    |
| Induced sputum eosinophil count | 43 (45.3) | 32 (55.2)         | 11 (29.7)             | 0.015    |
| Exhaled nitric oxide         | 25 (26.3)   | 21 (36.2)         | 4 (10.8)              | 0.006    |
| Aspirin provocation test     | 16 (16.8)   | 15 (25.9)         | 1 (2.7)               | 0.003    |

Values are presented as number of patients (%). Bolded values denote statistical significance.

SPT, skin prick test; IgE, immunoglobulin E; CT, computed tomography.

*Comparison between allergists and pulmonologists.

### Table 3. Difficulties in the management of severe asthma

| Factor                          | Total (n=95) | Allergists (n=58) | Pulmonologists (n=37) | P value* |
|---------------------------------|-------------|-------------------|-----------------------|----------|
| Lack of effective medication    | 83 (87.4)   | 53 (91.4)         | 30 (81.1)             | 0.141    |
| Concern over adverse reactions to medication | 45 (47.4) | 24 (41.4)         | 21 (56.8)             | 0.143    |
| Concern over insurance cuts     | 24 (25.3)   | 16 (27.6)         | 8 (21.6)              | 0.514    |
| Fear of misdiagnosis            | 23 (24.2)   | 17 (29.3)         | 6 (16.2)              | 0.146    |
| Poor patient compliance         | 23 (24.2)   | 16 (27.6)         | 7 (18.9)              | 0.336    |
| Lack of severe asthma guideline | 18 (18.9)   | 12 (20.7)         | 6 (16.2)              | 0.587    |
| Difficulty with the patient relationship | 13 (13.7) | 6 (10.3)          | 7 (18.9)              | 0.236    |
| High medical costs              | 12 (12.6)   | 8 (13.8)          | 4 (10.8)              | 0.670    |

Values are presented as number of patients (%). Lack of effective drugs (87.4%), concern over adverse reactions to medications (47.4%), concern over insurance cuts (25.3%), fear of misdiagnosis (24.2%), poor patient compliance (24.2%), lack of severe asthma guidelines (18.9%), difficulty with the patient relationship (13.7%), and high medical costs (12.6%).

*Comparison between allergists and pulmonologists.
Allergists and pulmonologists of severe asthma and COPD were surveyed about the prevalence of ACOS (chronic obstructive pulmonary disease overlap syndrome). The specialists estimated that the percentage of ACOS patients among patients with severe asthma was 30.1% ± 21.3%. The mean values of the percentages of ACOS in overall asthma and severe asthma patients from the allergists' perspective were not different from those of pulmonologists. However, the estimated percentage of ACOS in patients with COPD was higher according to allergists than pulmonologists (35.5% ± 23.6% vs. 22.6% ± 14.8%; P = 0.002).

Next, we attempted to identify the most important features in ACOS diagnosis. As ACOS is accepted as a subgroup of both asthma and COPD, we assumed that diagnosis of ACOS in patients with asthma would be different than diagnosis in patients with COPD. Thus, we asked the subjects two questions regarding the diagnosis of ACOS. First, we asked the specialists to classify each feature as a major or a minor criterion for the diagnosis of ACOS. The features most often classified as major criteria (≥70% of the subjects) included a history of smoking (83.2%), persistently low forced expiratory volume in 1 second (FEV1 <80% of the predicted value, 81.1%), and low variation of FEV1 over time (71.6%). The features not consistently classified as major criteria (<70%) included emphysema on chest images (67.4%), negative bronchodilator response (BDR) (54.7%), older age at onset of symptoms (≥40 years) (52.6%), no personal history of allergic diseases (27.4%), negative SPTs (14.7%), no family history of allergic diseases (11.6%), no sputum eosinophilia (9.5%), low serum total IgE (7.4%), and low exhaled nitric oxide concentration (3.2%) (Table 4). Allergists selected emphysema on chest images as a major criterion more frequently than pulmonologists (75.9% vs. 54.1%; P = 0.039), while pulmonologists more commonly selected older age at onset of symptoms (70.3% vs. 41.4%; P = 0.010) and low serum total IgE (13.5% vs. 3.4%; P = 0.010).

The second question asked about the diagnosis of ACOS in patients with COPD. Most specialists responded that high FEV1 variation over time (86.3%), positive BDR (79.0%), a personal history of allergic disease (73.7%) and positive airway hyper-responsiveness (AHR) (71.6%) were major criteria for the diagnosis of ACOS in patients with COPD. The features less often classified as major criteria were no history of smoking (57.3%), young age of onset (<40 years) (63.2%), no history of smoking (56.8%), positive SPT (54.7%), high serum total IgE (50.5%), sputum eosinophilia (45.3%), family history of allergic diseases (40.0%), wheeze (35.8%), high exhaled nitric oxide concentration (31.6%), and lack of emphysema on chest images (23.2%) (Table 5). Of these features, the allergists tended to favour exhaled nitric oxide concentration in the determination of ACOS among COPD patients compared to pulmonologists (41.4% vs. 16.2%; P = 0.008). However, the pulmonologists selected high serum total IgE as the diagnostic criterion for ACOS more frequently than allergists (54.1% vs. 48.3%; P = 0.040).

Finally, we asked if ACOS in asthma and ACOS in COPD were the same disease. Overall, 37.9% of the specialists agreed that the two diseases are the same. More allergists tended to agree with this suggestion than pulmonologists (44.8% vs. 27.0%; P =
These findings suggest that the specialists consider different criteria for the diagnosis of ACOS in patients with asthma compared to patients with COPD. Moreover, the diagnostic criteria for ACOS perceived by the allergists were somewhat dissimilar to those perceived by the pulmonologists.

**DISCUSSION**

Severe asthma and ACOS are receiving more attention due to serious morbidity and poor clinical outcomes. However, ambiguity and uncertainty still exist in the understanding of severe asthma and ACOS, even among specialists. In this study, we es-

---

Table 4. Major and minor criteria for the diagnosis of ACOS in patients with asthma

| Characteristic* | Criterion classification | Total (n=95) | Allergists (n=58) | Pulmonologists (n=37) | P value† |
|-----------------|--------------------------|-------------|------------------|-----------------------|---------|
| History of smoking | Major | 79 (83.2) | 46 (79.3) | 33 (89.2) | 0.210 |
| | Minor | 16 (16.8) | 12 (20.7) | 4 (10.8) |
| | No | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Persistently low FEV1 (<80% predicted) | Major | 77 (81.1) | 45 (77.6) | 32 (86.5) | 0.527 |
| | Minor | 12 (12.6) | 9 (15.5) | 3 (8.1) |
| | No | 6 (6.3) | 4 (6.9) | 2 (5.4) |
| Low FEV1 variation over time | Major | 66 (71.6) | 41 (70.7) | 27 (73.0) | 0.251 |
| | Minor | 23 (24.2) | 13 (22.4) | 10 (27.0) |
| | No | 4 (4.2) | 4 (6.9) | 0 (0.0) |
| Emphysema on chest images | Major | 64 (67.4) | 44 (75.9) | 20 (54.1) | 0.039 |
| | Minor | 26 (27.4) | 13 (22.4) | 13 (35.1) |
| | No | 5 (5.3) | 1 (1.7) | 4 (10.8) |
| Negative BDR | Major | 52 (54.7) | 30 (51.7) | 22 (59.5) | 0.710 |
| | Minor | 36 (37.9) | 23 (39.7) | 13 (35.1) |
| | No | 7 (7.4) | 5 (8.6) | 2 (5.4) |
| Age of onset ≥ 40 years | Major | 50 (52.6) | 24 (41.4) | 26 (70.3) | 0.010 |
| | Minor | 39 (41.1) | 28 (48.3) | 11 (29.7) |
| | No | 6 (6.3) | 6 (10.3) | 0 (0.0) |
| No personal history of allergic disease | Major | 26 (27.4) | 14 (24.1) | 12 (32.4) | 0.117 |
| | Minor | 53 (55.8) | 31 (53.4) | 22 (59.5) |
| | No | 16 (16.8) | 13 (22.4) | 3 (8.1) |
| Negative SPT | Major | 14 (14.7) | 10 (17.2) | 4 (10.8) | 0.095 |
| | Minor | 51 (53.7) | 26 (44.8) | 25 (67.6) |
| | No | 30 (31.6) | 22 (37.9) | 8 (21.6) |
| No family history of allergic disease | Major | 11 (11.6) | 6 (10.3) | 5 (13.5) | 0.267 |
| | Minor | 60 (63.2) | 34 (58.6) | 26 (70.3) |
| | No | 24 (25.3) | 18 (31.0) | 6 (16.2) |
| No sputum eosinophilia (<3%) | Major | 9 (9.5) | 4 (6.9) | 5 (13.5) | 0.396 |
| | Minor | 57 (60.0) | 34 (58.6) | 23 (62.2) |
| | No | 29 (30.5) | 20 (34.5) | 9 (24.3) |
| Low serum total IgE | Major | 7 (7.4) | 2 (3.4) | 5 (13.5) | 0.010 |
| | Minor | 51 (53.7) | 27 (46.6) | 24 (64.9) |
| | No | 37 (39.0) | 29 (50.0) | 8 (21.6) |
| Low exhaled nitric oxide (<25 ppb) | Major | 3 (3.2) | 2 (3.4) | 1 (2.7) | 0.732 |
| | Minor | 44 (46.3) | 25 (43.1) | 19 (51.4) |
| | No | 48 (50.5) | 31 (53.4) | 17 (45.9) |

Values are presented as number of patients (%). Bolded values denote statistical significance. ACOS, asthma-chronic obstructive pulmonary disease overlap syndrome; FEV1, forced expiratory volume in 1 second; BDR, bronchodilator response; SPT, skin prick test; IgE, immunoglobulin E.

*Characteristics are listed in descending order in terms of % response of major criteria; †comparison between allergists and pulmonologists.
~estimated the percentages and phenotypes of severe asthma and ACOS in the clinical practices of specialists. We also evaluated the patterns of diagnosis and treatment of severe asthma in clinical practice. Thus, we assessed the current perceptions of severe asthma and ACOS among specialists in airway diseases using a questionnaire-based survey.

| Characteristic*                  | Criterion classification | Total (n=95) | Allergists (n=58) | Pulmonologists (n=37) | P-value† |
|----------------------------------|--------------------------|--------------|-------------------|-----------------------|----------|
| High FEV1 variation over time    | Major                    | 82 (86.3)    | 50 (86.2)         | 32 (86.5)             | 0.479    |
|                                  | Minor                    | 11 (11.6)    | 6 (10.3)          | 5 (13.5)              |          |
|                                  | No                       | 2 (2.1)      | 2 (3.4)           | 0 (1.0)               |          |
| Positive BDR                     | Major                    | 75 (79.0)    | 50 (86.2)         | 25 (67.6)             | 0.094    |
|                                  | Minor                    | 15 (15.8)    | 6 (10.3)          | 9 (24.3)              |          |
|                                  | No                       | 5 (5.3)      | 2 (3.4)           | 3 (8.1)               |          |
| Personal history of allergic diseases | Major                | 70 (73.7)    | 41 (70.7)         | 29 (78.4)             | 0.708    |
|                                  | Minor                    | 22 (23.2)    | 15 (25.9)         | 7 (19.9)              |          |
|                                  | No                       | 3 (3.2)      | 2 (3.4)           | 1 (2.7)               |          |
| Positive AHR test                | Major                    | 68 (71.6)    | 40 (69.0)         | 28 (75.7)             | 0.496    |
|                                  | Minor                    | 21 (22.1)    | 13 (22.4)         | 8 (21.6)              |          |
|                                  | No                       | 6 (6.3)      | 5 (8.6)           | 1 (2.7)               |          |
| Age of onset < 40 years          | Major                    | 60 (63.2)    | 28 (48.3)         | 32 (84.9)             | 0.256    |
|                                  | Minor                    | 30 (31.6)    | 25 (43.1)         | 5 (27.0)              |          |
|                                  | No                       | 5 (5.3)      | 5 (8.6)           | 0 (8.1)               |          |
| No history of smoking           | Major                    | 54 (56.8)    | 31 (53.4)         | 23 (62.2)             | 0.555    |
|                                  | Minor                    | 36 (37.9)    | 23 (39.7)         | 13 (35.1)             |          |
|                                  | No                       | 5 (5.3)      | 4 (6.9)           | 1 (2.7)               |          |
| Positive SPT                    | Major                    | 52 (54.7)    | 32 (55.2)         | 20 (54.1)             | 0.091    |
|                                  | Minor                    | 33 (34.7)    | 17 (29.3)         | 16 (43.2)             |          |
|                                  | No                       | 10 (10.5)    | 9 (15.5)          | 1 (2.7)               |          |
| High serum total IgE            | Major                    | 48 (50.5)    | 28 (48.3)         | 20 (54.1)             | 0.040    |
|                                  | Minor                    | 34 (35.8)    | 18 (31.0)         | 16 (43.2)             |          |
|                                  | No                       | 13 (13.7)    | 12 (20.7)         | 1 (2.7)               |          |
| Sputum eosinophilia (>3%)       | Major                    | 43 (45.3)    | 31 (53.4)         | 12 (32.4)             | 0.118    |
|                                  | Minor                    | 41 (43.2)    | 22 (37.9)         | 19 (51.4)             |          |
|                                  | No                       | 11 (11.6)    | 5 (8.6)           | 6 (16.2)              |          |
| Family history of allergic diseases | Major                | 38 (40.0)    | 20 (34.5)         | 18 (48.6)             | 0.072    |
|                                  | Minor                    | 46 (48.4)    | 28 (48.3)         | 18 (48.6)             |          |
|                                  | No                       | 11 (11.6)    | 10 (17.2)         | 1 (2.7)               |          |
| Wheeze                          | Major                    | 34 (35.8)    | 19 (32.8)         | 15 (40.5)             | 0.742    |
|                                  | Minor                    | 50 (52.6)    | 32 (55.2)         | 18 (48.6)             |          |
|                                  | No                       | 11 (11.6)    | 7 (12.1)          | 4 (10.8)              |          |
| High exhaled nitric oxide (>50 ppb) | Major                | 30 (31.6)    | 24 (41.4)         | 6 (16.2)              | 0.008    |
|                                  | Minor                    | 39 (41.1)    | 17 (29.3)         | 22 (59.5)             |          |
|                                  | No                       | 26 (27.4)    | 17 (29.3)         | 9 (24.3)              |          |
| Lack of emphysema on chest images | Major                | 22 (23.2)    | 15 (25.9)         | 7 (18.9)              | 0.720    |
|                                  | Minor                    | 60 (63.2)    | 35 (60.3)         | 25 (67.6)             |          |
|                                  | No                       | 13 (13.7)    | 8 (13.8)          | 5 (13.5)              |          |

Values are presented as number of patients (%). Bolded values denote statistical significance. ACOS, asthma-chronic obstructive pulmonary disease overlap syndrome; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; BDR, bronchodilator response; AHR, airway hyper-responsiveness; SPT, skin prick test; IgE, immunoglobulin E.

*Characteristics are listed in descending order in terms of % response of major criteria; †comparison between allergists and pulmonologists.
It is frequently said that 5%-10% of patients with asthma have severe asthma. However, this estimation varies depending on the diagnostic criteria and population. Studies so far have shown that approximately 3%-10% of patients with asthma in the general population suffer from severe asthma. However, the proportion of patients with severe asthma was determined to be 10%-25% of asthma patients in a specialty clinic. In our survey, the specialists’ estimation of severe asthma prevalence was high, although estimates varied widely. As most respondents of this survey worked in university hospitals or general hospitals, these percentages reflect the population of severe asthma in specialist clinics, not in the general population. The reasons for the diversity of estimated prevalence could be due to the lack of a given definition of severe asthma, heterogeneity of the institutions, and patient populations.

Definitions of severe or refractory asthma have changed over time, and there is currently no universally accepted definition. However, it is acknowledged that severe asthma is heterogeneous and has many phenotypes and endotypes. Therefore, we asked specialists how frequently they observed each clinical subtype or characteristic of severe asthma, based on the diagnostic criteria of refractory asthma used by the ATS. Interestingly, the most common clinical features of severe asthma were aggravation of symptoms by stepping down treatment and frequent exacerbations, while the proportion of uncontrolled symptoms at GINA treatment steps 4-5 was not so high. These findings suggest that many patients with severe asthma require prolonged and higher medications to maintain control even though their symptoms are controlled.

Phenotypes are defined as composite and observable characteristics resulting from the interaction of genetic and environmental effects. Phenotype-based asthma management has not been well emphasized to date, with the exception of the identification of allergic asthma for the use of anti-IgE. More than 90% of the specialists in this study measured peripheral blood cell eosinophil count and allergic status using total and serum specific IgE and a SPT for aeroallergens. Approximately 65% used a chest CT, usually to manage severe asthma. The chest CT is useful for the differential diagnosis of other respiratory diseases that mimic asthma, and for identification of emphysema, a feature of COPD. Measurement of sputum eosinophils, exhaled nitric oxide, and the aspirin provocation test were more frequently used by allergists than pulmonologists, suggesting that phenotyping of asthma has been more widely accepted by allergy specialists. In the near future, asthma phenotyping will be more important in cases of severe asthma, with introduction of new biological agents targeting type 2 inflammation, such as interleukin (IL)-5, IL-4, and IL-13. Problems in the treatment of severe asthma include the lack of guidance in the determination of asthma phenotypes and difficulty in the measurement and integration of various biomarkers. Accurate, informative, and easy-to-measure biomarkers are needed to phenotype asthma.

One of the primary difficulties in the management of severe asthma is that there is no effective add-on treatment when asthma is uncontrolled, despite the use of high-dose ICS and LABA. Lack of effective medication leads to the use of multiple medications to achieve and maintain asthma control. Moreover, polypharmacy in severe asthma is associated with increased direct medical costs and risk of adverse reactions. Thus, we asked how many patients used add-on medications in addition to high-dose ICS/LABA and leukotriene receptor antagonists. As shown in Figure 3, the most frequently prescribed medications were theophylline and tiotropium, as recommended in the GINA guidelines. Oral corticosteroids were more commonly prescribed at low doses (<20 mg/day) than at high doses (≥20 mg/day). Omalizumab, which was the only available biological agent approved for use in severe allergic asthma at the time of this survey, was used in a small number of patients with severe asthma. Despite its proven efficacy in clinical trials and clinical practice, the low use of omalizumab might be associated with one or more disadvantages, including high cost, complexity of administration, risk of serious adverse reactions, lack of efficacy, and relatively narrow indication in severe asthma. In the survey regarding the difficulties of management of severe asthma, the lack of effective medications and concern over adverse reactions were most commonly selected (Table 3). The results of this study showed that the off-label use of medications, such as high-dose ICS, multiple ICs, roflumilast, methotrexate, and cyclosporin, was also being tried in some patients with severe asthma. While these medications have failed to show significant overall efficacy in patients with severe asthma, some patients with specific phenotypes or endotypes might benefit from specific treatment that is not currently approved. As a future medication, personalized precision medicine targeting a treatable phenotype or pathophysiology is expected to be available soon for the management of severe asthma. In addition to the sophisticated use of available medications, we must develop new effective therapeutic agents for severe asthma with fewer adverse effects.

ACOS is currently receiving a great deal of attention. Studies to date have shown that its clinical outcome is poorer than asthma or COPD alone, with a higher rate of exacerbations and greater mortality. While the prevalence of ACOS among chronic airway diseases has been reported to be approximately 20%, it varies depending on the study design, population, and definition of ACOS. In our survey, the percentage of ACOS patients was estimated to be 20.7% in patients with asthma, 38.0% in patients with severe asthma, and 30.1% in patients with COPD. This estimate is based on patient populations of each subject, not the general population, reflecting actual experience in a specialty clinic. The problem is that there is no universally accepted working definition of ACOS. Thus, it is likely that even a specialist might use their own definition of ACOS. The difference in the diagnostic criteria leads to a wide variance of the prevalence.
of ACOS in various types of studies. Furthermore, the application of different ACOS definitions or diagnostic criteria also leads to dissimilar clinical characteristics and outcomes. Interestingly, most diagnostic criteria were developed to define ACOS among patients with COPD, not among patients with asthma. As in the consensus criteria of ACOS in Spain, we asked the specialists to name the key features of COPD that are considered in the diagnosis of ACOS in patients with asthma. The characteristics of COPD were given in detail, and were classified as major or minor criteria by the respondents. Intriguingly, most respondents selected a history of smoking as a major criterion for ACOS in asthma. It is obvious that smoking affects lung function decline and contributes to the development of COPD. However, considering that a high percentage of COPD patients have never smoked, it seems an oversimplification to consider only smoking in the determination of ACOS. In addition to smoking, a spirometric index such as persistently low FEV1 or low FEV1 variation over time were selected as major characteristics of ACOS. These findings suggest that specialist support in the diagnosis of ACOS in patients with asthma should be made in consideration of smoking and changes in lung function over time. Emphysema was also selected as a major criterion by allergists more than pulmonologists. Although the presence of emphysema does not indicate COPD per se, COPD must be considered in asthma patients showing emphysema on chest images. Furthermore, emphysema by itself might be a link between asthma and COPD, both in smokers and in patients who have never smoked.

There have been attempts by a Spanish group and a global expert panel, the ATS roundtable discussion, to define diagnostic criteria by consensus. Both consensus definitions included the previous diagnosis of asthma and positive BDRs as major criteria. While a positive BDR was selected as a major criterion by many respondents, the highest scores were given to high FEV1 variation over time and AHR. In a recent study by Tkacova et al., AHR, not BDR, was found to be associated with accelerated lung function decline and higher mortality in patients with COPD. These findings suggest that AHR should be considered as a key element in the determination of ACOS. The previous history of asthma diagnosis before 40 years of age was classified as a major criterion in previous consensus documents on ACOS. However, many adult patients with asthma in some countries, including Korea, experience symptoms onset at a very old age, and the duration of asthma is very short. Given this late diagnosis of asthma, the previous diagnosis before 40 years of age could not be practically and universally used. Thus, we did not include the previous diagnosis of asthma as a candidate characteristic of ACOS in this study. Rather, we added a personal history of allergic diseases, which was selected as a major criterion by many specialists. As rhinitis and atopy are considered significant risk factors for the future development of asthma, it seems reasonable to consider a past history of allergies when diagnosing ACOS in patients with COPD.

Two different pathways may exist for the development of ACOS; it may stem from asthma, or from COPD. Thus, some experts suggest that ACOS can be divided into asthma with features of COPD (COPD-like asthma) and COPD with features of asthma (asthma-like COPD). Our data support this idea, as more than half of the respondents (62.1%) did not agree that asthma patients diagnosed with ACOS are the same population as COPD patients diagnosed with ACOS. As the previously developed consensus definition of ACOS was developed in order to define ACOS as a subtype of COPD, there are limitations to applying that definition to the whole population of ACOS patients. ACOS cannot be a single disease entity or a subtype of COPD, as stated in the GINA update in 2017. It is acknowledged that asthma is a heterogeneous disease, as is COPD. Therefore, it is apparent that ACOS, which shares features of both asthma and COPD, is a heterogeneous disease and has various phenotypes. Understanding of ACOS varies even among specialists. Universal application of the definition of ACOS looks tempting, but is impractical both in clinical practice and research.

A few studies regarding the perceptions and insights of ACOS have been published, primarily by pulmonologists. The advantages of our study are the inclusion of both pulmonologists and allergists, and the comparison of their insights and clinical practices concerning severe asthma and ACOS. Some differences according to subspecialty (allergy or pulmonology) were found in responses to some questions of severe asthma and ACOS. Differences included the use of diagnostic tests in asthma phenotyping, assessment of the percentage of the ACOS population among COPD patients, and the definition of ACOS among patients with asthma or COPD. Previous studies also showed that the characteristics and management of asthma differed between allergists and pulmonologists. We speculate that this discord according to subspecialty resulted from the variance in patient populations and different perspectives on asthma and COPD.

However, the results of this study must be interpreted with caution. As this survey was based on the views of the participants and the response rate of the invited subjects was low, the findings cannot be over-generalized. In this regard, the difference between allergists and pulmonologists cannot be over-emphasized, since the respondents do not represent for each subspecialty group. Moreover, as this was a nationwide survey in Korea, it might reflect country- or ethnic-specific conditions of clinical practices and insurance status. Lastly, because the responses of the respondents were based on their own experience and perceptions, not on the objective assessment from the patient cohort or registry, the results of this study might be different from the real-world assessments.

In conclusion, the results showed that specialists’ estimation of the prevalence of severe asthma and ACOS varies widely. Their understandings and practices of severe asthma and ACOS di-
ACKNOWLEDGMENTS

We thank all the participants who gave their valuable time for this survey. This study is supported by grant from the Korean Academy of Asthma, Allergy and Clinical Immunology.

ORCID

Sang-Heon Kim https://orcid.org/0000-0001-3989-4444
Ji Yong Moon https://orcid.org/0000-0003-2459-3448
Jae Hyun Lee https://orcid.org/0000-0002-0790-0071
Ga-Young Ban https://orcid.org/0000-0002-7961-742X
Sujeong Kim https://orcid.org/0000-0002-2494-9216
Mi-Ae Kim https://orcid.org/0000-0003-1253-0675
Joo-Hee Kim https://orcid.org/0000-0002-1572-5149
Min-Hye Kim https://orcid.org/0000-0002-1775-3733
Chan-Sun Park https://orcid.org/0000-0003-0113-8354
So-Young Park https://orcid.org/0000-0002-5224-3077
Hyouk-Soo Kwon https://orcid.org/0000-0001-7695-997X
Jae-Woo Kwon https://orcid.org/0000-0003-1639-3606
Jae-Woo Jung https://orcid.org/0000-0002-3411-745X
Hye-Ryun Kang https://orcid.org/0000-0002-2317-4201
Jong-Sook Park https://orcid.org/0000-0003-4128-9085
Tae-Bum Kim https://orcid.org/0000-0001-5663-0640
Heung-Woo Park https://orcid.org/0000-0002-6970-3228
You Sook Cho https://orcid.org/0000-0001-8767-2667
Kwang-Ha Yoo https://orcid.org/0000-0001-9969-2657
Yeong-Mok Oh https://orcid.org/0000-0003-0116-4883
Byung-Jae Lee https://orcid.org/0000-0001-6940-0836
An-Soo Jang https://orcid.org/0000-0001-5343-023X
Sang-Heon Cho https://orcid.org/0000-0002-7644-4649
Hae-Sim Park https://orcid.org/0000-0003-2614-0303
Choon-Sik Park https://orcid.org/0000-0003-2977-0255
Ho Joo Yoon https://orcid.org/0000-0002-4674-4863

REFERENCES

1. Chung KE, Wenzel SE, Brozel JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-73.
2. Bousquet J, Manzoumanis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Bleecker ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010;126:926-38.
3. Custovic A, Johnston SL, Pavord I, Gaga M, Fabbri L, Bel EH, et al. EAACI position statement on asthma exacerbations and severe asthma. Allergy 2013;68:1520-31.
4. Sullivan SD, Wenzel SE, Bresnahan BW, Zheng B, Lee JH, Pritchard M, et al. Association of control and risk of severe asthma-related events in severe or difficult-to-treat asthma patients. Allergy 2007;62:555-60.
5. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009;64:728-35.
6. Zeki AA, Schivo M, Chan A, Albertson TE, Louie S. The asthma-COPD overlap syndrome: a common clinical problem in the elderly. J Allergy (Cairo) 2011;2011:861926.
7. Diaz-Guzman E, Khosravi M, Mannino DM. Asthma, chronic obstructive pulmonary disease, and mortality in the U.S. population. COPD 2011;8:400-7.
8. Hardlin M, Silverman EK, Barf RG, Hansel NN, Schroeder JD, Make BJ, et al. The clinical features of the overlap between COPD and asthma. Respir Res 2011;12:127.
9. van Boven JR, Román-Rodríguez M, Palmer JF; Toledo-Pons N, Cossio BG, Soriano JB. Comorbidly, pattern, and impact of asthma-COPD overlap syndrome in real life. Chest 2016;149:1011-20.
10. Rhee CK, Yoon HK, Yoo KH, Kim YS, Lee SW, Park YB, et al. Medical utilization and cost in patients with overlap syndrome of chronic obstructive pulmonary disease and asthma. COPD 2014;11:163-70.
11. Cazzola M, Rogliani P. Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? J Allergy Clin Immunol 2016;138:977-83.
12. Reddel HK. Treatment of overlapping asthma-chronic obstructive pulmonary disease: can guidelines contribute in an evidence-free zone? J Allergy Clin Immunol 2015;136:546-52.
13. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention [Internet]. [place unknown]; Global Initiative for Asthma; 2017 [cited 2017 Aug 12]. Available from: http://www.ginasthma.org.
14. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD [Internet]. [place unknown]; Global Initiative for Chronic Obstructive Lung Disease; 2017 [cited 2017 Aug 12]. Available from: http://www.goldcopd.org/.
15. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000;162:2341-51.
16. von Bülow A, Kriegerbaum M, Backer V, Porsbjerg C. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract 2014;2:759-67.
17. Heffkamp PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol Pract 2015;3:896-902.
18. Springer J, Sc蔑e D, Shitrit D. Severe and non-severe asthma in the community: a large electronic database analysis. Respir Med 2017;123:131-9.
19. Kim TB, Park CS, Bae YJ, Cho YS, Moon HB; COREA Study Group. Factors associated with severity and exacerbation of asthma: a baseline analysis of the cohort for reality and evolution of adult asthma in Korea (COREA). Ann Allergy Asthma Immunol 2009;103:311-7.
20. Chung KE, Godard P, Adelroth E, Ayres J, Barnes N, Barnes P, et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Soc-
Perceptions of Severe Asthma and ACOS

21. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 2012;42:650-8.
22. Fajt ML, Wenzel SE. Development of new therapies for severe asthma. Allergy Asthma Immunol Res 2017;9:3-14.
23. Chung KF. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. J Intern Med 2016;279: 192-204.
24. O’Neill S, Sweeney J, Patterson CC, Menzies-Gow A, Niven R, Man sur AH, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Dif ficult Asthma Registry. Thorax 2015;70:368-72.
25. Menezza E, Galeone C, Formisano D, Castagnetti C, Ruggiero P, Simonazzi A, et al. Real-life efficacy of omalizumab after 9 years of follow-up. Allergy Asthma Immunol Res 2017;9:368-72.
26. Caminati M, Senna G, Stefanizzi G, Bellamoli R, Longhi S, Chiecchio Bianchi E, et al. Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience. BMC Pulm Med 2016;16:128.
27. Ferrando M, Bagnasco D, Varricchi G, Bernardi S, Bragan tini A, Pas salaqua G, et al. Personalized medicine in allergy. Allergy Asthma Immunol Res 2017;9:15-24.
28. Gibson PG, McDonald VM. Asthma-COPD overlap 2015: now we are six. Thorax 2015;70:683-91.
29. Wurst KE, Kelly-Reif K, Bushnell GA, Pascoe S, Barnes N. Understanding asthma-chronic obstructive pulmonary disease overlap syndrome. Respir Med 2016;110:1-11.
30. Jo YS, Lee J, Yoon HI, Kim DK, Yoo CG, Lee CH. Different prevalence and clinical characteristics of asthma-chronic obstructive pulmonary disease overlap syndrome according to accepted criteria. Ann Allergy Asthma Immunol 2017;118:606-703.e1.
31. Soler-Cataluña JJ, Cosío B, Izquierdo JL, López-Campos JL, Marín JM, Agiero R, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012;48:331-7.
32. Menezes AM, Montes de Oca M, Pérez-Padilla R, Nadeau G, Wehrmeister FC, Lopez-Varela MV, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest 2014;145:297-304.
33. Kankaanranta H, Harju T, Kilpeläinen M, Mazur W, Lehto JT, Kata jisto M, et al. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines. Basic Clin Pharmacol Toxicol 2015;116:291-307.
34. Sin DD, Miravitlles M, Mannino DM, Soriano JB, Price D, Celli BR, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J 2016;48: 664-73.
35. Perret JL, Dharmage SC, Matheson MC, Johns DF, Gurrin LC, Burgess JA, et al. The interplay between the effects of lifetime asthma, smoking, and atopy on fixed airflow obstruction in middle age. Am J Respir Crit Care Med 2013;187:42-8.
Supplement 1. Survey Questionnaire

Basic information

1. What is your age? (______________)

2. What is your gender?
   1) male
   2) female

3. What is your specialty board?
   1) allergy
   2) pulmonology
   3) other specialty board
   4) not a specialist

4. What kind of institution do you practice in?
   1) university hospital
   2) general hospital
   3) hospital
   4) private clinic
   5) other

5. Which age group do you usually see in your practice?
   1) children
   2) adults
   3) both

I. Diagnosis of severe asthma

1. What percentage of patients with severe asthma in your practice have the following clinical features? (The sum of the subtypes may be over 100%.)

| Clinical Feature                                           | Percentage |
|------------------------------------------------------------|------------|
| Uncontrolled asthma symptoms despite gina step 4-5 treatment | __________% |
| Controlled asthma symptoms at gina step 4-5, but symptoms are aggravated by stepping down | __________% |
| Serious exacerbation (≥1 hospitalization per year)          | __________% |
| Frequent exacerbation (≥2 uses of oral corticosteroid rescue per year) | __________% |

2. What is the approximate percentage of patients with severe asthma among the total number of asthma patients in your practice? (__________%)

3. The phenotype of severe asthma is known to be diverse. Please indicate the usual tests for the classification of severe asthma phenotypes in your practice.

| Test                                      | Yes | No |
|-------------------------------------------|-----|----|
| Serum total ige                           | ☐   | ☐  |
| Peripheral blood cell count               | ☐   | ☐  |
| Induced sputum eosinophil count           | ☐   | ☐  |
| Exhaled nitric oxide                      | ☐   | ☐  |
| Allergen skin tests or serum specific ige measurement | ☐   | ☐  |
| Chest computed tomography (ct)            | ☐   | ☐  |
| Aspirin provocation test                  | ☐   | ☐  |
4. What percentage of patients with severe asthma in your practice have the following diseases?

| Disease                              | Percentage |
|--------------------------------------|------------|
| Allergic rhinitis                    |            |
| Gastro-oesophageal reflux disease (GERD) |            |
| Obesity                              |            |
| Sleep apnoea                         |            |
| Depression or anxiety disorder       |            |
| Aspirin intolerance                  |            |

II. Treatment of severe asthma

1. Of the patients with severe asthma you are seeing, what percentages use the following drugs as controller medications in addition to high-dose inhaled corticosteroids (ICS) / long-acting beta-2 agonists (LABA) and leukotriene receptor antagonists?

| Drug                  | Percentage |
|-----------------------|------------|
| Very high dose ics    |            |
| Two or more ics       |            |
| Oral corticosteroids (≥20 mg/day) |  |
| Oral corticosteroids (<20 mg/day) |  |
| Anti-ige              |            |
| Theophylline          |            |
| Tiotropium            |            |
| Roflumilast           |            |
| Methotrexate          |            |
| Cyclosporine          |            |

2. What is most difficult when you see patients with severe asthma? (Multiple answers possible)
   1) no effective add-on drugs
   2) concern over misdiagnosis
   3) difficulty with the patient relationship
   4) insurance cuts
   5) low patient compliance
   6) high medical expenses
   7) concern over adverse drug reactions
   8) lack of severe asthma guidelines

III. Asthma-COPD overlap syndrome (ACOS)

1. What is the approximate percentage of patients with ACOS among the total number of asthma patients in your practice? (__________%)

2. What is the approximate percentage of patients with severe asthma among the total number of asthma patients in your practice? (__________%)

3. What is the approximate percentage of the patients with ACOS among the total number of COPD patients in your practice? (__________%)
4. This question is about the ACOS criteria among patients initially diagnosed with and treated for asthma. The list includes possible items which can be considered in the diagnosis of ACOS among asthma patients. Please check if each item in the list could be a major or minor criterion or not.

| Diagnostic criterion                              | Major | Minor | No |
|--------------------------------------------------|-------|-------|----|
| Older age of onset (≥ 40 years old)              | ☐     | ☐     | ☐  |
| History of smoking                               | ☐     | ☐     | ☐  |
| No personal history of allergic diseases         | ☐     | ☐     | ☐  |
| No family history of allergic diseases           | ☐     | ☐     | ☐  |
| Negative skin prick test                         | ☐     | ☐     | ☐  |
| Low serum total IgE                              | ☐     | ☐     | ☐  |
| Persistently low FEV1 < 80% predicted            | ☐     | ☐     | ☐  |
| Low FEV1 variation over time                     | ☐     | ☐     | ☐  |
| Negative bronchodilator response                 | ☐     | ☐     | ☐  |
| No sputum eosinophilia (<3%)                     | ☐     | ☐     | ☐  |
| Low exhaled nitric oxide (< 25 ppb)              | ☐     | ☐     | ☐  |
| Emphysema on chest images                        | ☐     | ☐     | ☐  |

5. This question is about the ACOS criteria among patients initially diagnosed with and treated for COPD. The list includes possible items considered in the diagnosis of ACOS among asthma patients. Please check if each item in the list could be a major or minor criterion or not.

| Diagnostic criterion                              | Major | Minor | No |
|--------------------------------------------------|-------|-------|----|
| Younger age of onset (< 40 years old)            | ☐     | ☐     | ☐  |
| Wheeze                                           | ☐     | ☐     | ☐  |
| No history of smoking                            | ☐     | ☐     | ☐  |
| Personal history of allergic diseases            | ☐     | ☐     | ☐  |
| Family history of allergic diseases              | ☐     | ☐     | ☐  |
| Positive skin prick test                         | ☐     | ☐     | ☐  |
| High serum total IgE                             | ☐     | ☐     | ☐  |
| High FEV1 variation over time                    | ☐     | ☐     | ☐  |
| Positive bronchodilator response (12% and 200 mL)| ☐     | ☐     | ☐  |
| Positive airway hyper-responsiveness test        | ☐     | ☐     | ☐  |
| Sputum eosinophilia (>3%)                        | ☐     | ☐     | ☐  |
| High exhaled nitric oxide (>50 ppb)              | ☐     | ☐     | ☐  |
| Lack of emphysema on chest images                | ☐     | ☐     | ☐  |

6. Do you agree that asthma patients diagnosed with ACOS are the same population as COPD patients diagnosed with ACOS?
   1) Yes
   2) No